Article Information
History
- December 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Asona J. Lui, MD, PhD1,
- Karoline Kallis, PhD1,
- Allison Y. Zhong1,2,
- Troy S. Hussain1,
- Christopher Conlin, PhD1,
- Leonardino A. Digma2,
- Nikki Phan1,
- Ian T. Mathews, PhD1,2,
- Deondre D. Do3,
- Mariluz Rojo3,
- Roshan Karunamuni, PhD1,
- Joshua Kuperman, PhD4,
- Anders M. Dale, PhD4,5,6,
- Rebecca Rakow-Penner, MD, PhD3,4,
- Michael E. Hahn, MD, PhD4 and
- Tyler M. Seibert, MD, PhD1,3,4,*
- 1Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, CA, USA
- 2UC San Diego School of Medicine, La Jolla, CA, USA
- 3Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, CA,USA
- 4Department of Radiology, UC San Diego School of Medicine, La Jolla, CA, USA
- 5Department of Neurosciences, UC San Diego School of Medicine, La Jolla, CA, USA
- 6Halıcıoğlu Data Science Institute, UC San Diego School of Medicine, La Jolla, CA, USA
- ↵*Corresponding Author:
Tyler M. Seibert, MD, PhD Assistant Professor, Department of Radiation Medicine and Applied Sciences, Department of Radiology, Department of Bioengineering, Center for Multimodal Imaging and Genetics, University of California San Diego, 9500 Gilman Dr. Mail Code 0861, La Jolla, CA 92093-0861, tseibert{at}ucsd.edu, T: 858-246-5988, F: 858-246-0501
Posted December 14, 2022.
ReIGNITE RT Boost: An international study testing the accuracy and feasibility of using restriction spectrum imaging (RSI) MRI to guide intraprostatic tumor target volume for radiotherapy boost
